VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | Updates at ASH in CLL: U2

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses his excitement for updates from the UNITY-CLL study which will be presented at ASH 2020. The study compares the safety and efficacy of a combination of the novel anti-CD20 monoclonal antibody, ublituximab, and umbralisib (U2), a novel PI3Kγ inhibitor, with chlorambucil and obinutuzumab in both frontline and relapsed/refractory patients with chronic lymphocytic leukemia (CLL). The study regimen is highly anticipated and has the potential to significantly benefit patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Matthew Davids, MD, has participated in scientific advisory boards, has done consultancy work or has received honoraria from AbbVie, Adaptive Biosciences, Ascentage Pharma, AstraZeneca, BeiGene, Celgene, Eli Lilly, Genentech, Janssen, MEI Pharma, Merck, Novartis, Pharmacyclics, TG Therapeutics, Verastem and Research to Practice; and has received research funding from Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics and Verastem.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter